Rockwell Medical Technologies (RMTI) 9.99 $RMTI
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 17, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Rockwell Medical Announces Triferic(TM) Iron Replacement Clinical Data Selected for Three Abstract Presentations at National Kidney Foundation Spring Clinical Meetings April 22-26, 2014 in Las Vegas, NV
GlobeNewswire - Mon Apr 14, 7:08AM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that three individual abstracts for Triferic have been selected by the National Kidney Foundation for presentation at their Spring Clinical Meetings, April 22-26, 2014 in Las Vegas, Nevada. Triferic is the Company's late-stage investigational iron-replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis.
Today’s Top Biotech Stories: Albany Molecular Research, Rockwell Medical, and Celgene
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 24, 8:16AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Albany Molecular...
Rockwell Medical Submits New Drug Application for Triferic(TM) for the Treatment of Iron Replacement in Chronic Kidney Disease Patients on Hemodialysis
GlobeNewswire - Mon Mar 24, 7:05AM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Triferic (soluble ferric pyrophosphate citrate), the Company's late-stage investigational iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis. The NDA submission is based primarily on the datasets derived from the Triferic Phase 3 registration study program, and includes efficacy and safety data from additional studies.
What's Next for Rockwell Medical?
Eileen Rojas, The Motley Fool - Motley Fool - Fri Mar 14, 1:30PM CDT
Rockwell Medical, Inc posted a loss in its latest fourth quarter and full year 2013 report, but there appears to be a light at the end of the tunnel for its dialysis treatment business. At its current price, the company is an...
Buffett Can't Get Enough of This Stock
Keith Speights, The Motley Fool - Motley Fool - Sun Mar 09, 7:00AM CDT
Warren Buffett's Berkshire Hathaway began scooping up shares of DaVita Healthcare Partners , a dialysis provider, back in 2011. The trend continued last week: SEC filings revealed that Berkshire purchased another 1.15 million shares. This...
Agios Pharmaceuticals (AGIO) Surges: Stock Moves 26.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:18AM CST
Agios Pharmaceuticals, Inc. (AGIO) was a big mover last session, as the company saw its shares rise by over 26% on the day.
Rockwell Medical to Host Investor Meeting With Nephrology Key Opinion Leader on March 6, 2014 in New York City
GlobeNewswire - Wed Mar 05, 10:47AM CST
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will host a Key Opinion Leader Breakfast on Thursday, March 6, 2014, beginning at 8:00am Eastern Time, in New York City. Rockwell's management team will provide a brief overview of the Company's strategies to drive long-term growth, and Key Opinion Leader, Anatole Besarb, MD, will discuss how Rockwell's Triferic(TM), currently under investigation for the treatment of iron replacement in dialysis patients, will play an integral role in the anemia and renal space.
Rockwell Medical, Inc. Reports Fourth Quarter 2013 Results
GlobeNewswire - Wed Feb 26, 3:09PM CST
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the fourth quarter and year ended December 31, 2013.
5 Hated Earnings Stocks You Should Love
at The Street - Tue Feb 25, 12:24PM CST
These heavily shorted stocks could get squeezed much higher on bullish earnings.
Rockwell Medical wins Japanese patent for Triferic
M2 - Mon Feb 24, 6:22AM CST
US-based biopharmaceutical company Rockwell Medical (NASDAQ:RMTI) revealed on Friday the receipt of the Japanese patent for its late-stage investigational iron-replacement drug Triferic, for patients with chronic kidney disease receiving hemodialysis.
Rockwell Medical Receives Japanese Patent Issuance for Triferic(TM) GMP Formulation
Marketwire - Fri Feb 21, 7:30AM CST
Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it has received notice from the Japan Patent Office that it has obtained patent issuance for its GMP formulation of Triferic, the Company's late-stage investigational iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis.
Rockwell Medical Schedules 4th Quarter 2013 Investor Conference Call
Marketwire - Tue Feb 18, 7:01AM CST
Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will hold its quarterly conference call to discuss fourth quarter results on Wednesday, February 26, 2014 at 4:30pm Eastern Time. The Company plans to release results after market close the same day.
Rockwell Medical Completes Long-Term Safety Study for Iron Maintenance Drug Triferic(TM)
Marketwire - Tue Feb 04, 7:45AM CST
Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, today announced its large-scale, long-term safety study is complete. This final Phase 3 study and the two CRUISE clinical efficacy and safety studies were conducted in support of the New Drug Application (NDA) for marketing approval of Triferic. Triferic is the Company's late-stage investigational iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis.
Michelin and Continental to Continue their Market Dominance in Germany's Tyre Market through 2018, says TechSci Research
PR Newswire - Tue Feb 04, 7:40AM CST
Germany is the largest economy in Europe and is also one of the leading tyres markets, globally. Moreover, the country is the fourth largest passenger car producer, globally, after China, US and Japan, which market Germany a large market for OEMs (Original Equipment Manufacturer). On the other hand, the replacement tyre market is also significant because of high passenger car population, with the country's car ownership level estimated at about 530 passenger cars per thousand people in Germany in 2012.In addition, the country has the second largest logistics market across the global, which boosts the overall demand for commercial vehicles as well as tyres in the country.
Rockwell Medical to Present Two Abstracts on Triferic(TM) Maintenance Iron Therapy at ISN Nexus Symposium April 3-6, 2014 in Bergamo, Italy
Marketwire - Tue Jan 28, 7:31AM CST
Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that two individual abstracts have been selected by the Scientific Program Committee for Poster Presentation during the ISN Nexus Symposium 2014 that will take place April 3-6, 2014 in Bergamo, Italy.
Children Give Value to One Ghana Cedis in Vodafone Essay Competition
by Masahudu Ankiilu Kunateh - All Africa Global Media - Tue Jan 14, 12:38PM CST
Vodafone Ghana's drive to empower young ones to reach beyond the limits of their imagination is yielding fruits. Through its One Ghana writing competition dubbed - "What can you do with GHc1", children are resolute to become game-changers in the country.
2013 Report on the International Nephrology and Urology Devices Market - Industry Analysis, Size, Share, Trends and Forecast to 2018
M2 - Fri Jan 10, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/t8gg8c/nephrology_and) has announced the addition of the "2013 Report on the International Nephrology and Urology Devices Market - Industry Analysis, Size, Share, Trends and Forecast to 2018" report to their offering. Nephrology and urology devices are commonly used for treatment of kidney and urinary system related problems such as chronic kidney disease (CKD) and end stage renal disease (ESRD), kidney stone, benign prostatic hyperplasia (BPH), urinary incontinence and pelvic organ prolapse. A slow growing awareness of urinary diseases and causes of renal failure has led to a large population suffering from CKD, diabetes and ESRD. Growing market for dialysis due to rising incidences of chronic kidney diseases (CKD) along with increasing aging population is the major driver for this market. Increasing awareness about the benefits such as reduced treatment and recovery time among renal disease patients is also influencing the demand for nephrology and urology devices. Some other driving factors include innovation in urology devices, increasing healthcare spending and growing refurbished devices market particularly for lithotripters in Asia-Pacific and other developing regions. This also leaves consumers in Europe and North America to revamp their clinics and hospitals with new innovative technologies. Aging is the most common factor responsible for all types of urology diseases. It is expected that a large size of population will undergo kidney disease treatment which will increase the demand for these devices across the world. Key Topics Covered: 1 Preface 2 Executive Summary 3 Nephrology and Urology Devices Market Dynamics 4 Nephrology and Urology Devices Market, by Device Type 5 Nephrology and Urology Devices Market, by Geography 6 Market Share Analysis of Key Players, 2011 7 Company Profile Analysis Companies Mentioned: - Asahi Kasei Corp. - B Braun Group - Baxter International Inc. - C. R. Bard Inc. - Cook Group Incorporated - Dornier Medtech - Fresenius Medical Care - Nikkiso Co. Ltd. - Nipro Corporation - Nxstage Medical Inc - Rockwell Medical Technologies, Inc - Terumo Corporation For more information visit http://www.researchandmarkets.com/research/t8...rology_and
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 17, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Rockwell Medical Announces Triferic(TM) Iron Replacement Clinical Data Selected for Three Abstract Presentations at National Kidney Foundation Spring Clinical Meetings April 22-26, 2014 in Las Vegas, NV
GlobeNewswire - Mon Apr 14, 7:08AM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that three individual abstracts for Triferic have been selected by the National Kidney Foundation for presentation at their Spring Clinical Meetings, April 22-26, 2014 in Las Vegas, Nevada. Triferic is the Company's late-stage investigational iron-replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis.
Today’s Top Biotech Stories: Albany Molecular Research, Rockwell Medical, and Celgene
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 24, 8:16AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Albany Molecular...
Rockwell Medical Submits New Drug Application for Triferic(TM) for the Treatment of Iron Replacement in Chronic Kidney Disease Patients on Hemodialysis
GlobeNewswire - Mon Mar 24, 7:05AM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Triferic (soluble ferric pyrophosphate citrate), the Company's late-stage investigational iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis. The NDA submission is based primarily on the datasets derived from the Triferic Phase 3 registration study program, and includes efficacy and safety data from additional studies.
What's Next for Rockwell Medical?
Eileen Rojas, The Motley Fool - Motley Fool - Fri Mar 14, 1:30PM CDT
Rockwell Medical, Inc posted a loss in its latest fourth quarter and full year 2013 report, but there appears to be a light at the end of the tunnel for its dialysis treatment business. At its current price, the company is an...
Buffett Can't Get Enough of This Stock
Keith Speights, The Motley Fool - Motley Fool - Sun Mar 09, 7:00AM CDT
Warren Buffett's Berkshire Hathaway began scooping up shares of DaVita Healthcare Partners , a dialysis provider, back in 2011. The trend continued last week: SEC filings revealed that Berkshire purchased another 1.15 million shares. This...
Agios Pharmaceuticals (AGIO) Surges: Stock Moves 26.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:18AM CST
Agios Pharmaceuticals, Inc. (AGIO) was a big mover last session, as the company saw its shares rise by over 26% on the day.
Rockwell Medical to Host Investor Meeting With Nephrology Key Opinion Leader on March 6, 2014 in New York City
GlobeNewswire - Wed Mar 05, 10:47AM CST
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will host a Key Opinion Leader Breakfast on Thursday, March 6, 2014, beginning at 8:00am Eastern Time, in New York City. Rockwell's management team will provide a brief overview of the Company's strategies to drive long-term growth, and Key Opinion Leader, Anatole Besarb, MD, will discuss how Rockwell's Triferic(TM), currently under investigation for the treatment of iron replacement in dialysis patients, will play an integral role in the anemia and renal space.
Rockwell Medical, Inc. Reports Fourth Quarter 2013 Results
GlobeNewswire - Wed Feb 26, 3:09PM CST
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the fourth quarter and year ended December 31, 2013.
5 Hated Earnings Stocks You Should Love
at The Street - Tue Feb 25, 12:24PM CST
These heavily shorted stocks could get squeezed much higher on bullish earnings.
Rockwell Medical wins Japanese patent for Triferic
M2 - Mon Feb 24, 6:22AM CST
US-based biopharmaceutical company Rockwell Medical (NASDAQ:RMTI) revealed on Friday the receipt of the Japanese patent for its late-stage investigational iron-replacement drug Triferic, for patients with chronic kidney disease receiving hemodialysis.
Rockwell Medical Receives Japanese Patent Issuance for Triferic(TM) GMP Formulation
Marketwire - Fri Feb 21, 7:30AM CST
Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it has received notice from the Japan Patent Office that it has obtained patent issuance for its GMP formulation of Triferic, the Company's late-stage investigational iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis.
Rockwell Medical Schedules 4th Quarter 2013 Investor Conference Call
Marketwire - Tue Feb 18, 7:01AM CST
Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will hold its quarterly conference call to discuss fourth quarter results on Wednesday, February 26, 2014 at 4:30pm Eastern Time. The Company plans to release results after market close the same day.
Rockwell Medical Completes Long-Term Safety Study for Iron Maintenance Drug Triferic(TM)
Marketwire - Tue Feb 04, 7:45AM CST
Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, today announced its large-scale, long-term safety study is complete. This final Phase 3 study and the two CRUISE clinical efficacy and safety studies were conducted in support of the New Drug Application (NDA) for marketing approval of Triferic. Triferic is the Company's late-stage investigational iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis.
Michelin and Continental to Continue their Market Dominance in Germany's Tyre Market through 2018, says TechSci Research
PR Newswire - Tue Feb 04, 7:40AM CST
Germany is the largest economy in Europe and is also one of the leading tyres markets, globally. Moreover, the country is the fourth largest passenger car producer, globally, after China, US and Japan, which market Germany a large market for OEMs (Original Equipment Manufacturer). On the other hand, the replacement tyre market is also significant because of high passenger car population, with the country's car ownership level estimated at about 530 passenger cars per thousand people in Germany in 2012.In addition, the country has the second largest logistics market across the global, which boosts the overall demand for commercial vehicles as well as tyres in the country.
Rockwell Medical to Present Two Abstracts on Triferic(TM) Maintenance Iron Therapy at ISN Nexus Symposium April 3-6, 2014 in Bergamo, Italy
Marketwire - Tue Jan 28, 7:31AM CST
Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that two individual abstracts have been selected by the Scientific Program Committee for Poster Presentation during the ISN Nexus Symposium 2014 that will take place April 3-6, 2014 in Bergamo, Italy.
Children Give Value to One Ghana Cedis in Vodafone Essay Competition
by Masahudu Ankiilu Kunateh - All Africa Global Media - Tue Jan 14, 12:38PM CST
Vodafone Ghana's drive to empower young ones to reach beyond the limits of their imagination is yielding fruits. Through its One Ghana writing competition dubbed - "What can you do with GHc1", children are resolute to become game-changers in the country.
2013 Report on the International Nephrology and Urology Devices Market - Industry Analysis, Size, Share, Trends and Forecast to 2018
M2 - Fri Jan 10, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/t8gg8c/nephrology_and) has announced the addition of the "2013 Report on the International Nephrology and Urology Devices Market - Industry Analysis, Size, Share, Trends and Forecast to 2018" report to their offering. Nephrology and urology devices are commonly used for treatment of kidney and urinary system related problems such as chronic kidney disease (CKD) and end stage renal disease (ESRD), kidney stone, benign prostatic hyperplasia (BPH), urinary incontinence and pelvic organ prolapse. A slow growing awareness of urinary diseases and causes of renal failure has led to a large population suffering from CKD, diabetes and ESRD. Growing market for dialysis due to rising incidences of chronic kidney diseases (CKD) along with increasing aging population is the major driver for this market. Increasing awareness about the benefits such as reduced treatment and recovery time among renal disease patients is also influencing the demand for nephrology and urology devices. Some other driving factors include innovation in urology devices, increasing healthcare spending and growing refurbished devices market particularly for lithotripters in Asia-Pacific and other developing regions. This also leaves consumers in Europe and North America to revamp their clinics and hospitals with new innovative technologies. Aging is the most common factor responsible for all types of urology diseases. It is expected that a large size of population will undergo kidney disease treatment which will increase the demand for these devices across the world. Key Topics Covered: 1 Preface 2 Executive Summary 3 Nephrology and Urology Devices Market Dynamics 4 Nephrology and Urology Devices Market, by Device Type 5 Nephrology and Urology Devices Market, by Geography 6 Market Share Analysis of Key Players, 2011 7 Company Profile Analysis Companies Mentioned: - Asahi Kasei Corp. - B Braun Group - Baxter International Inc. - C. R. Bard Inc. - Cook Group Incorporated - Dornier Medtech - Fresenius Medical Care - Nikkiso Co. Ltd. - Nipro Corporation - Nxstage Medical Inc - Rockwell Medical Technologies, Inc - Terumo Corporation For more information visit http://www.researchandmarkets.com/research/t8...rology_and
